Navigation path

Left navigation

Additional tools

Other available languages: FR DE

IP/09/1344

Brussels, 23 rd September 2009

Mergers: Commission clears proposed acquisition of EBEWE SP by Novartis

The European Commission has approved under the EU Merger Regulation the proposed acquisition of the Austrian generic pharmaceuticals company EBEWE Spezial–Pharma Holding by Novartis of Switzerland, a pharmaceutical company with both originator and generic activities. The Commission concluded that the proposed transaction would not significantly impede effective competition in the European Economic Area ("EEA") or any substantial part of it.

Novartis is active in the development, production and distribution of both originator and generic pharmaceutical products and animal health products on a world-wide basis. EBEWE SP is active in the manufacture and distribution of specialty generic pharmaceutical products (with a focus on generic oncology products) and in the contract manufacturing of finished dose pharmaceuticals for other pharmaceutical companies. Generics are copies of originator drugs which become available once the patent for the originator drug expires.

The Commission 's examination found that the transaction would not raise competition concerns as significant market shares and overlaps between the parties' activities would only arise in a small number of markets where a sufficient number of credible competitors would remain after the proposed transaction.

More information on the case will be available at:

http://ec.europa.eu/competition/mergers/cases/index/m111.html#m_5555


Side Bar